Globalu00a0radiotherapy marketu00a0is forecasted to value over USD 7 billion by 2026 end and register a CAGR of over 4% from the forecast period 2019-2026. Latest technological advancements, increasing focus of increasing awareness regarding the benefits and growing prevalence of cancer is driving the market. Based on the figures released by WHO, cancer is one of the major life-threatening diseases and it accounted for the deaths of around 9.7 million people worldwide in 2018. The rising usage of particle therapy for the diagnosis of cancer alongside improving reimbursement policy is boosting the market. Emerging markets alongside rising investments of government and private sectors are fueling the market growth. Improvements and further amendments in image-guided radiotherapy are propelling the market.u00a0 The market is classified into product type, type, application, end-user, and region. In terms of type, the market is segmented into radiotherapy, internal beam radiotherapy, systemic radiotherapy, and external beam radiotherapy. External beam radiotherapy is expected to dominate the growth of the market. The precision and accuracy offered by external beam radiotherapy for targeting tumour is better than other methods, which is the primary reason for segment proliferation. In addition, external beam radiotherapy offers less risk of exposure to radiation. Due to these factors, end-users have opted for external beam radiotherapy thus inflating the market.u00a0 Based on product type, external beam radiotherapy is expected to achieve the highest CAGR. Less maintenance and equipment costs of linear accelerators alongside precise radiation offered by cyberknife is expected to bolster the market. The 360-degree radiation treatment offered by tomotherapy is adding further growth opportunities thus spurring the market. In terms of application, prostate cancer segment of external beam radiotherapy is expected to showcase significant growth over the forecast period. Minimally long-term risks associated with external beam radiotherapy coupled with the rising cases of prostate cancer is driving the growth of the market. In addition, the growing adoption of external beam radiation therapy (EBRT) systems for the treatment of breast cancer is expected to expand the market. On the basis of end-user, hospitals are expected to hold the major market share. The rising cases of cancer have resulted in hospitals demanding more deployment of advanced radiotherapy equipment which has stimulated the market. The rapid expansion of hospitals in developed economies alongside favorable government initiatives aimed towards hospitals inculcating more advanced radiotherapy systems is boosting the market.u00a0 In terms of regions, North America dictates the market growth. The easy accessibility, high adoption of advanced diagnostic equipment and rising healthcare expenditure in countries like Canada and the US are stimulating the market in the region. Asia-Pacific region is expected to showcase exponential growth during the forecast period. Rapidly improving healthcare infrastructure alongside growing per capita income in emerging economies like China, Japan and India are bolstering the market in the region. In addition, favorable policies launched by the governments of these countries are expected to boost the market growth in the region. u00a0 Major players of the market areu00a0Hitachi Ltd., IsoRay Medical, Inc, Ion Beam Applications SA, Provision Healthcare, Varian Medical Systems, Inc, Mevion Medical Systems, Inc, Panacea Medical Technologies Pvt.Ltd, Accuray Incorporated and Elekta AB.u00a0 Competitive Landscape:u00a0 u25cf u00a0 u00a0 Varian Medical Systems in 2017, opened its center in Jundiai, Brazil. The move will increase the access to advanced radiotherapy equipment and treatment across Brazil u25cf u00a0 u00a0 Varian Medical Systems launched an innovative treatment platform called Halcyon Treatment System. The system eases treatment delivery with increased speed and high-quality plans Request a Sample Reportu00a0@u00a0https://www.futurewiseresearch.com/request-sample.aspx?id=2347&page=requestsample Global Radiotherapy Market Segmentationu00a0 By Product Typeu00a0 u25cf u00a0 u00a0External Beam Radiotherapyu00a0 u25aa u00a0 u00a0 u00a0Linear Accelerators u25aa u00a0 u00a0 u00a0Particle Therapy System u25aa u00a0 u00a0 u00a0Conventional Cobalt-60 Teletherapy Units u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u25cf u00a0 u00a0Internal Beam Radiotherapy/Brachytherapyu00a0 u25aa u00a0 u00a0 u00a0Seeds u25aa u00a0 u00a0 u00a0Applicators u25aa u00a0 u00a0 u00a0Afterloaders u25aa u00a0 u00a0 u00a0Electronic Brachytherapy Products u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u25cf u00a0 u00a0Systemic Radiotherapyu00a0 u25aa u00a0 u00a0 u00a0Iobenguane (I-131) u25aa u00a0 u00a0 u00a0Samarium-153 u25aa u00a0 u00a0 u00a0Rhenium-186 u00a0u00a0 By Typeu00a0 u25cf u00a0 u00a0External Beam Radiotherapyu00a0 u25aa u00a0 u00a0 u00a0Image-Guided Radiotherapy u25aa u00a0 u00a0 u00a03d Conformal Radiotherapy u25aa u00a0 u00a0 u00a0Intensity-Modulated Radiotherapy u25aa u00a0 u00a0 u00a0Stereotactic Therapy u25aa u00a0 u00a0 u00a0Particle Therapy u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u25cf u00a0 u00a0Internal Beam Radiotherapyu00a0 u25aa u00a0 u00a0 u00a0Low-Dose-Rate Brachytherapy u00a0 u00a0 u00a0 u25aa u00a0 u00a0 u00a0High-Dose-Rate Brachytherapy u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u25aa u00a0 u00a0 u00a0Pulsed-Dose-Rate Brachytherapy u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u25cf u00a0 u00a0Systemic Radiotherapyu00a0 u25aa u00a0 u00a0 u00a0Intravenous Radiotherapy u00a0 u25aa u00a0 u00a0 u00a0Oral Radiotherapy u25aa u00a0 u00a0 u00a0Instillation Radiotherapy u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 u00a0 By Applicationu00a0 u25cf u00a0 u00a0External Beam Radiation Therapyu00a0 u25aa u00a0 u00a0 u00a0Prostate Cancer u25aa u00a0 u00a0 u00a0Breast Cancer u25aa u00a0 u00a0 u00a0Lung Cancer u25aa u00a0 u00a0 u00a0Head and Neck Cancer u25aa u00a0 u00a0 u00a0Colorectal Cancer u25aa u00a0 u00a0 u00a0Other Cancers u00a0 u25cf u00a0 u00a0Internal Beam Radiotherapy/Brachytherapyu00a0 u25aa u00a0 u00a0 u00a0Prostate Cancer u25aa u00a0 u00a0 u00a0Gynecological Cancer u25aa u00a0 u00a0 u00a0Breast Cancer u25aa u00a0 u00a0 u00a0Cervical Cancer u25aa u00a0 u00a0 u00a0Penile Cancer u25aa u00a0 u00a0 u00a0Other Cancers u00a0 By End Useru00a0 u25cf u00a0 u00a0 Hospital u00a0 u00a0 u00a0 u00a0 u25cf u00a0 u00a0 Independent Radiotherapy Centers u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0 u00a0u00a0 By Region:u00a0 u25cf u00a0 u00a0 North America u25cf u00a0 u00a0u00a0Europe u25cf u00a0 u00a0 Asia Pacific u25cf u00a0 u00a0 Latin America u25cf u00a0 u00a0 Rest of the World Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=2347&page=askfordiscount FutureWise Key Takeaways u25cf u00a0Growth Prospects u25cf u00a0SWOT Analysis u25cf u00a0Key Trends u25cf u00a0Key data-points affecting market growth u00a0 Objectives of the Study: u2022 To provide with an exhaustive analysis on the global radiotherapy market by type, by product type, by application, by end-user and by regionu00a0 u2022 To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) u2022 To evaluate and forecast micro-markets and the overall marketu00a0 u2022 To predict the market size, in key regions (along with countries)u2014North America, Europe, Asia Pacific, Latin America and the rest of the world u2022 To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions u2022 Profiling of companies to evaluate their market shares, strategies, financial and core competencies Table of Contents 1 Introductionu00a0 u00a0u00a0 u00a01.1 Objectives of the Studyu00a0 u00a0u00a0 u00a01.2 Market Definitionu00a0 u00a0u00a0 u00a01.3 Market Scopeu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a01.3.1 Markets Covered u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a01.3.2 Years Considered for the Study u00a0u00a0 u00a01.4 Currencyu00a0 u00a0u00a0 u00a01.5 Stakeholdersu00a0 u00a0 2 Research Methodologyu00a0 u00a0u00a0 u00a02.1 Research Datau00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.1.1 Secondary Data u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.1.1.1 Key Data From Secondary Sources u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.1.2 Primary Data u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.1.2.1 Key Data From Primary Sources u00a0u00a0 u00a02.2 Market Size Estimationu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.2.1 Product-Based Market Estimation u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.2.2 Primary Research Validation u00a0u00a0 u00a02.3 Market Breakdown and Data Triangulationu00a0 u00a0u00a0 u00a02.4 Research Limitations and Assumptionsu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.4.1 Limitations u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a02.4.2 Assumptions u00a0 3 Executive Summaryu00a0 4 Premium Insightsu00a0 u00a0u00a0 u00a04.1 Radiotherapy Market Overviewu00a0 u00a0u00a0 u00a04.2 Europe: External Radiotherapy Market, By Type, 2019u00a0 u00a0u00a0 u00a04.3 Internal Beam Radiotherapy/Brachytherapy Market, By Product Typeu00a0 u00a0u00a0 u00a04.4 External Beam Radiotherapy Market, By Applicationu00a0 u00a0u00a0 u00a04.5 Regional Analysis: Radiotherapy Market, By End Useru00a0 u00a0u00a0 u00a04.6 Radiotherapy Market, By Countryu00a0 u00a0 5 Market Overviewu00a0 u00a0u00a0 u00a05.1 Introductionu00a0 u00a0u00a0 u00a05.2 Market Dynamicsu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.1 Drivers u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.1.1 Technological Advancements u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.1.2 Rising Prevalence of Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.1.3 Increasing Number of Conferences and Symposia Focusing on Spreading Awareness About the Benefits of Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.1.4 Growing Use of Particle Therapy for Cancer Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.2 Restraints u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.2.1 Lack of Adequate Healthcare Infrastructure u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.2.2 Shortage of Trained Personnel u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.2.3 Affordability and Accessibility of Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.2.4 Complex Nature of Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.3 Opportunities u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.3.1 Emerging Markets u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.3.2 Growing Government and Private Investments to Meet the Increasing Demand for Cancer Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.3.3 Improving Reimbursement Scenario u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.4 Challenges u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.4.1 Difficulties in Visualizing Tumors During Radiotherapy Procedures u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.2.4.2 Risk of Radiation Exposure u00a0u00a0 u00a05.3 Industry Trendsu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.3.1 Growing Adoption of Pencil-Beam Scanning u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a05.3.2 Growing Number of Collaborations and Acquisitions u00a0 6 Radiotherapy Market, By Product Typeu00a0 u00a0u00a0 u00a06.1 Introductionu00a0 u00a0u00a0 u00a06.2 External Beam Radiotherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1 Linear Accelerators u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.1 Conventional Linear Accelerators u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.1.1 Lower Equipment and Maintenance Cost Will Drive the Market for Conventional Linacs u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2 Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.1 Automation and Real-Time Tracking Features Have Ensured Demand for Stereotactic Advanced Linac u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.2 Gamma Knife u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.2.1 The Gamma Knife System is Considered A Gold Standard for Brain Tumor Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.3 Cyberknife u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.3.1 Cyberknife Offers A Precise Radiation Delivery Method With Specialized Tracking and Robotic Correction Capabilities u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.4 Tomotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.1.2.4.1 360-Degree (Helical) Radiation Treatment With Tomotherapy is Adding Growth Opportunities to This Segment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2 Particle Therapy Systems u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.1 Cyclotrons u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.1.1 Leading Players in the Particle Therapy Market Mainly Manufacture Cyclotronsu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.2 Synchrotrons u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.2.1 Increasing Investment for the Development of Synchrotron Facilities are Contributing to Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.3 Synchrocyclotrons u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.2.3.1 High Space Requirements of Synchrocyclotrons are Limiting Its Widespread Adoption u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.3 Conventional Cobalt-60 Teletherapy Units u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.2.3.1 High Cost and Risk of Radiation Exposure With Cobalt-60 Radioisotopes Have Hindered the Growth of This Segment u00a0u00a0 u00a06.3 Internal Beam Radiotherapy/Brachytherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.1 Seeds u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.1.1 Adverse Side-Effects Associated With Seeds Limit Their Adoption u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.2 Applicators u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.2.1 Manual Applicators Pose A High Risk of Radiation Exposure to the Patients and Staff u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.3 Afterloaders u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.3.1 Modern Afterloaders Offer Proper Positioning and Better Control of Isotopes Inside the Patient Body u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.4 Electronic Brachytherapy Products u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.3.4.1 Electronic Brachytherapy Requires Low Amount of Shielding Than Alternatives u00a0u00a0 u00a06.4 Systemic Radiotherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.1 Iobenguane (I-131) u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.1.1 Increasing Incidence of Thyroid Cancer is Driving the Growth of This Segment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.2 Samarium-153 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.2.1 Samarium-153 has Wide Applications for Bone Metastasis u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.3 Rhenium-186 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.3.1 Lack of Insurance Coverage With the Use of Rhenium-186 Restricting Its Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a06.4.4 Other Systemic Radiotherapy Products u00a0 7 Radiotherapy Market, By Typeu00a0 u00a0u00a0 u00a07.1 Introductionu00a0 u00a0u00a0 u00a07.2 External Beam Radiotherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.1 Image-Guided Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.1.1 Image-Guided Radiotherapy is Widely Used to the Treatment of Deep-Seated Tumors u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.2 3d Conformal Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.2.1 Multiple Beams With 3d-Crt Allow Precise Radiation Conforming to the Tumor Size and Shape u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.3 Intensity-Modulated Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.3.1 Volumetric Arc Therapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.3.1.1 Advancements in the Vmat Technology Driving Its Widespread Adoption u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.3.2 Tomotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.3.2.1 Minimal Exposure to Normal Tissues u2013 A Major Advantage of Tomotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.4 Stereotactic Therapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.4.1 Stereotactic Therapy Offers A Minimally Invasive Alternative to Ablation Surgeries u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.5 Particle Therapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.2.5.1 Particle Therapy is Increasingly Being Adopted as A Primary Mode of Treatment for Various Cancer Types u00a0u00a0 u00a07.3 Internal Beam Radiotherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.1 Low-Dose-Rate Brachytherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.1.1 Lower Risk of Radiation Exposure to the Surrounding Tissues With Ldr Supporting Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.2 High-Dose-Rate Brachytherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.2.1 Better Patient Care With HDR is Driving Its Widespread Adoption u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.3 Pulsed-Dose-Rate Brachytherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.3.3.1 Pulsed-Dose Rate Brachytherapy Combines the Advantages of HDR and Ldr Brachytherapy u00a0u00a0 u00a07.4 Systemic Radiotherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.1 Intravenous Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.1.1 Intravenous Route of Brachytherapy Results in Maximum Bioavailability u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.2 Oral Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.2.1 Longer Distribution Time Associated With the Oral Mode of Radiation Delivery Limiting Its Demand u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.3 Instillation Radiotherapy u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a07.4.3.1 Lesser Localization With Instillation Brachytherapy is Limiting Its Widespread Adoption u00a0 8 Radiotherapy Market, By Applicationu00a0 u00a0u00a0 u00a08.1 Introductionu00a0 u00a0u00a0 u00a08.2 External Beam Radiation Therapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.1 Prostate Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.1.1 High Incidence of Prostate Cancer Will Drive the Demand for Ebrt u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.2 Breast Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.2.1 Adoption of Advanced Ebrt Systems and Increasing Research Will Drive Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.3 Lung Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.3.1 Radiotherapy Can Be Used as Solo Or Combination Therapy for Lung Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.4 Head and Neck Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.4.1 Benefits of External Radiotherapy Will Support Its Use in Head and Neck Cancer Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.5 Colorectal Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.5.1 Availability of Alternative Therapeutic Options Limits the Growth of This Segment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.2.6 Other Cancers u00a0u00a0 u00a08.3 Internal Beam Radiotherapy/Brachytherapyu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.1 Prostate Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.1.1 Rapidity and Precision of Brachytherapy in Prostate Cancer Treatment Have Driven Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.2 Gynecological Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.2.1 Availability of Alternatives Hinders the Adoption of Brachytherapy in Gynecological Cancer Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.3 Breast Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.3.1 Precision and Rapid Treatment Times are Driving the Use of Brachytherapy in Breast Cancer Applications u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.4 Cervical Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.4.1 A Combination of Brachytherapy and Chemotherapy is Typically Used for Cervical Cancer Treatment u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.5 Penile Cancer u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.5.1 Advantages of Brachytherapy in Penile Cancer Treatment Have Driven Its Adoption u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a08.3.6 Other Cancers u00a0 9 Radiotherapy Market, By End Useru00a0 u00a0u00a0 u00a09.1 Introductionu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a09.1.1 Hospitals u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a09.1.1.1 Increasing Number of Small-Footprint Advanced Radiotherapy Products Promoting Their Adoption in Hospitals u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a09.1.2 Independent Radiotherapy Centers u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a09.1.2.1 Rising Consolidation of Healthcare Networks is Challenging the Growth of Freestanding Radiotherapy Centers u00a0 10 Radiotherapy Market, By Regionu00a0 u00a0u00a0u00a0 u00a010.1 Introductionu00a0 u00a0u00a0u00a0 u00a010.2 North Americau00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.2.1 US u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.2.1.1 Growing Government Initiatives Boosting the Adoption of Radiotherapy in the Us u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.2.2 Canada u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.2.2.1 Rising Cancer Incidence Driving the Demand for Radiotherapy in Canada u00a0u00a0u00a0 u00a010.3 Europeu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.1 Germany u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.1.1 Increasing Awareness of Novel and Advanced Radiotherapy Products A Key Factor Contributing to Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.2 France u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.2.1 Growing Government Initiatives Boosting the Adoption of Radiotherapy in France u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.3 UK u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.3.1 Leading Market Players Focusing on Expanding Their Product Offerings in the Uk u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.3.4 Rest of Europe u00a0u00a0u00a0 u00a010.4 Asia Pacificu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.1 China u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.1.1 Presence of A Large Number of Local Manufactures Supporting the Growth of the Radiotherapy Market in China u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.2 Japan u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.2.1 Rising Prevalence of Cancer is Driving the Adoption of Radiotherapy in Japan u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.3 India u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.3.1 Shortage of Skilled Radiotherapy Professionals in India is Restraining Market Growth u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a010.4.4 Rest of Asia Pacific u00a0u00a0u00a0 u00a010.5 Rest of the Worldu00a0 u00a0 11 Competitive Landscape (Page No. - 173) u00a0u00a0u00a0 u00a011.1 Introductionu00a0 u00a0u00a0u00a0 u00a011.2 Market Share Analysisu00a0 u00a0u00a0u00a0 u00a011.3 Competitive Scenariou00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.3.1 Product Launches and Approvals u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.3.2 Acquisitions u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.3.3 Expansions u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.3.4 Partnerships, Agreements, and Collaborations u00a0u00a0u00a0 u00a011.4 Vendor Dive Overviewu00a0 u00a0u00a0u00a0 u00a011.5 Vendor Inclusion Criteriau00a0 u00a0u00a0u00a0 u00a011.6 Vendor Diveu00a0 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.6.1 Vanguards u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.6.2 Innovators u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.6.3 Dynamic Players u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 u00a011.6.4 Emerging Companies u00a0 12 Company Profiles u00a0(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, FutureWise View)* u00a0u00a0u00a0 u00a012.1 Accuray Incorporatedu00a0 u00a0u00a0u00a0 u00a012.2 C. R. Bard, Inc.u00a0 u00a0u00a0u00a0 u00a012.3 Elektau00a0 u00a0u00a0u00a0 u00a012.4 Hitachi, Ltd.u00a0 u00a0u00a0u00a0 u00a012.5 IBA (Ion Beam Applications Sa)u00a0 u00a0u00a0u00a0 u00a012.6 Isoray Medical, Inc.u00a0 u00a0u00a0u00a0 u00a012.7 Mevion Medical Systems, Inc.u00a0 u00a0u00a0u00a0 u00a012.8 Optivus Proton Therapy, Inc.u00a0 u00a0u00a0u00a0 u00a012.9 Panacea Medical Technologies Pvt. Ltd.u00a0 u00a0u00a0u00a0 u00a012.10 P-Cure Ltd.u00a0 u00a0u00a0u00a0 u00a012.11 Provision Healthcare, LLC.u00a0 u00a0u00a0u00a0 u00a012.12 Sumitomo Heavy Industries, Ltdu00a0 u00a0u00a0u00a0 u00a012.13 Theragenics Corporationu00a0 u00a0u00a0u00a0 u00a012.14 Varian Medical Systems, Inc.u00a0 u00a0u00a0u00a0 u00a012.15 Viewray Inc.u00a0 *Details on FutureWise View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies. u00a0 Inquire further details about this report at:u00a0sales@futurewiseresearch.com About FutureWise Research: We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry u2013 a position secured for far more than the near future. Contact Us: Company Name:u00a0FutureWise Research Contact Person:u00a0 Vinay Thaploo Email:u00a0sales@futurewiseresearch.com Phone:u00a0 44 141 628 9353 / 1 970 279 4295 City:u00a0 Leeds Country:u00a0 United Kingdom Website:u00a0www.futurewiseresearch.com
★
★
★
★
★
165 views • 15 slides
